
|Articles|November 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
MB07133 gets orphan drug status
MB07133 gets orphan drug status
Advertisement
SAN DIEGOMetabasis Therapeutics' MB07133 has received orphan drug status from FDA for the treatment of hepatocellular carcinoma. MB07133 is a novel HepDirect prodrug of cytarabine monophosphate designed to produce the oncolytically active form, cytarabine triphosphate, in the liver tumor where it acts to inhibit cell proliferation and induce apoptosis.
Articles in this issue
over 18 years ago
MT103, BiTE antibody, enters phase II testing for ALLover 18 years ago
Sides dig in as ESA policy debate heats upover 18 years ago
Ixempra gets ok for resistant breast cancerover 18 years ago
ASCO adds Oncotype DX to marker guidelineover 18 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenover 18 years ago
Accelerated approval for Tasignaover 18 years ago
Oxidative stress inducer ups survival in advanced melanomaover 18 years ago
FDA removes partial hold on Telcyta clinical developmentover 18 years ago
Should all HER2+ pts receive adjuvant trastuzumab?over 18 years ago
R-CHOP is standard of care for advanced DLBCL patientsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Real World Outcomes of CAR T-Cell Therapy in Multiple Myeloma Including Older and Comorbid Patients
5



































